Trials / Completed
CompletedNCT04760769
Open-label Trial in Parkinson's Disease (PD)
58-Week Open-label Trial of Tavapadon in Parkinson's Disease (TEMPO-4 Trial)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 992 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Parkinson's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tavapadon | Participants will receive Tavapadon at a dose of (5 to 15) mg QD, orally during a 58-week treatment period. |
Timeline
- Start date
- 2021-02-24
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2021-02-18
- Last updated
- 2025-12-23
Locations
140 sites across 14 countries: United States, Australia, Bulgaria, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Poland, Serbia, Spain, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04760769. Inclusion in this directory is not an endorsement.